Financial Data and Key Metrics Changes - The Cigna Group reported full-year adjusted revenue of $275 billion, reflecting an 11% growth year-over-year [6][28] - Adjusted earnings per share (EPS) for the full year 2025 reached $29.84, a 9% increase compared to the previous year [6][30] - The company recorded after-tax special item charges of $483 million, equating to $1.82 per share [3][4] Business Line Data and Key Metrics Changes - Evernorth's specialty and care services business generated $26.7 billion in revenue, marking a 14% year-over-year growth [28] - The pharmacy benefit services business within Evernorth delivered $36.3 billion in revenue, with adjusted earnings of $1.2 billion [28] - Cigna Healthcare achieved adjusted revenues of $11.2 billion in Q4 2025, with pre-tax adjusted earnings of $734 million [30] Market Data and Key Metrics Changes - The company reported a 13% year-over-year growth in the number of specialty prescriptions in 2025 [15] - The specialty pharmacy market is projected to grow significantly, with a $400 billion-plus addressable market growing at a high single-digit secular growth rate [70] Company Strategy and Development Direction - Cigna Group is focused on evolving its business model to enhance customer experience and affordability, including a new rebate-free pharmacy benefits model [10][22] - The company aims to leverage partnerships and innovations to drive down healthcare costs and improve access to medications [11][12] - Strategic investments in specialty capabilities and pharmacy benefit services are intended to position the company for sustained growth [6][28] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to navigate a dynamic healthcare environment and achieve sustained growth [5][13] - The outlook for 2026 includes projected consolidated adjusted revenues of approximately $280 billion and adjusted EPS of at least $30.25 [30][31] - The company anticipates continued investment in infrastructure to support its new pharmacy benefits model, with a focus on affordability and transparency [31][66] Other Important Information - The company announced a global settlement with the Federal Trade Commission, which is expected to provide $7 billion in out-of-pocket cost relief over the next 10 years for customers [7][8] - Cigna Group returned over $5 billion to shareholders through dividends and share repurchases in 2025 [13] Q&A Session Summary Question: Discussion on PBM legislation and margin profile - Management indicated that the margin profile for the pharmacy benefit services (PBS) will remain similar despite the new model and regulatory changes, with no expected change in the growth algorithm [37][39] Question: Adoption of new pricing model - The entire Cigna Healthcare fully insured book is expected to adopt the new pricing model by 2027, with at least 50% of the Evernorth business adopting it by the end of 2028 [44][48] Question: Specialty business growth drivers - The specialty business experienced 14% top-line growth, driven by strong demand in various therapeutic areas and the increasing adoption of biosimilars [70][71]